All news

PTCT Upgraded by UBS -- Price Target Raised to $90.00

Alpha Vantage · GuruFocus · · AI-summarised by FinFlash

UBS upgraded PTC Therapeutics and raised its price target to $90.00, citing renewed confidence in the biotechnology company's development pipeline. GuruFocus data flags PTCT as 51.6% overvalued against a GF Value of $40.22, with a moderate GF Score of 59/100 on strong momentum but weak profitability and growth. Significant insider selling adds caution for investors weighing the upgrade.

Read original source

PTCT company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.